Patienterne fortsatte deres lamivudin- regime og blev allokeret til tillæg af entecavir 1 mg, én gang daglig (n = 51) eller placebo (n = 17) i 24 uger efterfulgt af yderligere 24 uger, hvor alle fik entecavir.
Patients continued their lamivudine-regimen and were assigned to add either entecavir 1 mg once daily (n = 51) or placebo (n = 17) for 24 weeks followed by an additional 24 weeks where all received entecavir.